J A Trubiano1, C Chen2, A C Cheng3, M L Grayson4, M A Slavin5, K A Thursky6. 1. Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia Department of Medicine, University of Melbourne, Parkville, VIC, Australia jason.trubiano@austin.org.au. 2. NHMRC National Centre of Antimicrobial Stewardship, Peter Doherty Institute, Parkville, VIC, Australia Department of Infectious Diseases, Royal Melbourne Hospital, Parkville, VIC, Australia. 3. Department of Epidemiology & Infectious Diseases, Alfred Health and Monash University, Melbourne, VIC, Australia. 4. Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia Department of Medicine, University of Melbourne, Parkville, VIC, Australia. 5. Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia Department of Infectious Diseases, Royal Melbourne Hospital, Parkville, VIC, Australia. 6. Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia NHMRC National Centre of Antimicrobial Stewardship, Peter Doherty Institute, Parkville, VIC, Australia Department of Infectious Diseases, Royal Melbourne Hospital, Parkville, VIC, Australia.
Abstract
BACKGROUND: The presence of antimicrobial allergy designations ('labels') often substantially reduces prescribing options for affected patients, but the frequency, accuracy and impacts of such labels are unknown. METHODS: The National Antimicrobial Prescribing Survey (NAPS) is an annual de-identified point prevalence audit of Australian inpatient antimicrobial prescribing using standardized definitions of guideline compliance, appropriateness and indications. Data were extracted for 2 years (2013-14) and compared for patients with an antimicrobial allergy label (AAL) and with no AAL (NAAL). RESULTS: Among 21 031 patients receiving antimicrobials (33 421 prescriptions), an AAL was recorded in 18%, with inappropriate antimicrobial use significantly higher in the AAL group versus the NAAL group (OR 1.12, 95% CI 1.05-1.22, P < 0.002). Patterns of antimicrobial use were significantly influenced by AAL, with lower β-lactam use (AAL versus NAAL; OR 0.47, 95% CI 0.43-0.50, P < 0.001) and higher quinolone (OR 2.07, 95% CI 1.83-2.34, P < 0.0001), glycopeptide (OR 1.59, 95% CI 1.38-1.83, P < 0.0001) and carbapenem (OR 1.74, 95% CI 1.43-2.13, P < 0.0001) use. In particular, among immunocompromised patients, AAL was associated with increased rates of inappropriate antimicrobial use (OR 1.68, 95% CI 1.21-2.30, P = 0.003), as well as increased use of quinolones (OR 1.88, 95% CI 1.16-3.03, P = 0.02) and glycopeptides (OR 1.82, 95% CI 1.17-2.84, P = 0.01). CONCLUSIONS: AALs are common and appear to be associated with higher rates of inappropriate prescribing and increased use of broad-spectrum antimicrobials. Improved accuracy in defining AALs is likely to be important for effective antimicrobial stewardship (AMS), with efforts to 'de-label' inappropriate AAL patients a worthwhile feature of future AMS initiatives.
BACKGROUND: The presence of antimicrobial allergy designations ('labels') often substantially reduces prescribing options for affected patients, but the frequency, accuracy and impacts of such labels are unknown. METHODS: The National Antimicrobial Prescribing Survey (NAPS) is an annual de-identified point prevalence audit of Australian inpatient antimicrobial prescribing using standardized definitions of guideline compliance, appropriateness and indications. Data were extracted for 2 years (2013-14) and compared for patients with an antimicrobial allergy label (AAL) and with no AAL (NAAL). RESULTS: Among 21 031 patients receiving antimicrobials (33 421 prescriptions), an AAL was recorded in 18%, with inappropriate antimicrobial use significantly higher in the AAL group versus the NAAL group (OR 1.12, 95% CI 1.05-1.22, P < 0.002). Patterns of antimicrobial use were significantly influenced by AAL, with lower β-lactam use (AAL versus NAAL; OR 0.47, 95% CI 0.43-0.50, P < 0.001) and higher quinolone (OR 2.07, 95% CI 1.83-2.34, P < 0.0001), glycopeptide (OR 1.59, 95% CI 1.38-1.83, P < 0.0001) and carbapenem (OR 1.74, 95% CI 1.43-2.13, P < 0.0001) use. In particular, among immunocompromised patients, AAL was associated with increased rates of inappropriate antimicrobial use (OR 1.68, 95% CI 1.21-2.30, P = 0.003), as well as increased use of quinolones (OR 1.88, 95% CI 1.16-3.03, P = 0.02) and glycopeptides (OR 1.82, 95% CI 1.17-2.84, P = 0.01). CONCLUSIONS: AALs are common and appear to be associated with higher rates of inappropriate prescribing and increased use of broad-spectrum antimicrobials. Improved accuracy in defining AALs is likely to be important for effective antimicrobial stewardship (AMS), with efforts to 'de-label' inappropriate AALpatients a worthwhile feature of future AMS initiatives.
Authors: Michael Ian Derrick; Kristina Blis Williams; Lincoln Morris Payne Shade; Elizabeth Jane Phillips Journal: J Allergy Clin Immunol Pract Date: 2017-09-22
Authors: S Khumra; J Chan; K Urbancic; T Worland; P Angus; R Jones; M L Grayson; J A Trubiano Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Jason A Trubiano; M Lindsay Grayson; Elizabeth J Phillips; Andrew J Stewardson; Karin A Thursky; Monica A Slavin Journal: J Antimicrob Chemother Date: 2018-11-01 Impact factor: 5.790
Authors: Jason A Trubiano; Cosby A Stone; M Lindsay Grayson; Karen Urbancic; Monica A Slavin; Karin A Thursky; Elizabeth J Phillips Journal: J Allergy Clin Immunol Pract Date: 2017-08-23
Authors: Cosby A Stone; Jason Trubiano; David T Coleman; Christine R F Rukasin; Elizabeth J Phillips Journal: Allergy Date: 2019-05-26 Impact factor: 13.146
Authors: Jason A Trubiano; Karin A Thursky; Andrew J Stewardson; Karen Urbancic; Leon J Worth; Cheryl Jackson; Wendy Stevenson; Michael Sutherland; Monica A Slavin; M Lindsay Grayson; Elizabeth J Phillips Journal: Clin Infect Dis Date: 2017-07-01 Impact factor: 9.079
Authors: Courtney M Dewart; Yuan Gao; Protiva Rahman; Awa Mbodj; Erinn M Hade; Kurt Stevenson; Courtney L Hebert Journal: Infect Control Hosp Epidemiol Date: 2018-07-23 Impact factor: 3.254
Authors: Jason A Trubiano; M Lindsay Grayson; Karin A Thursky; Elizabeth J Phillips; Monica A Slavin Journal: Med J Aust Date: 2018-06-18 Impact factor: 7.738
Authors: Kyra Y L Chua; Sara Vogrin; Susan Bury; Abby Douglas; Natasha E Holmes; Nixon Tan; Natasha K Brusco; Rebecca Hall; Belinda Lambros; Jacinta Lean; Wendy Stevenson; Misha Devchand; Kent Garrett; Karin Thursky; M Lindsay Grayson; Monica A Slavin; Elizabeth J Phillips; Jason A Trubiano Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079